Cabozantinib as a second-line treatment option in hepatocellular carcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cabozantinib as a second-line treatment option in hepatocellular carcinoma
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume -, Issue -, Pages 1-7
Publisher
Informa UK Limited
Online
2020-05-12
DOI
10.1080/17512433.2020.1767591
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cabozantinib: A Review in Advanced Hepatocellular Carcinoma
- (2019) Emma D. Deeks Targeted Oncology
- Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).
- (2019) Andrea S. Fung et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials
- (2019) Andrea Casadei Gardini et al. OncoTargets and Therapy
- Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma
- (2019) Linh Nguyen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life
- (2019) Daneng Li et al. Cancers
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
- (2018) J J Knox et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond
- (2018) Jean-Luc Raoul et al. CANCER TREATMENT REVIEWS
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma
- (2018) Masatoshi Kudo Liver Cancer
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
- (2018) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).
- (2018) Lorenza Rimassa et al. JOURNAL OF CLINICAL ONCOLOGY
- REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
- (2018) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- 148OAssessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
- (2018) T Yau et al. ANNALS OF ONCOLOGY
- 703PAssessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
- (2018) J F Blanc et al. ANNALS OF ONCOLOGY
- Second-line Treatments of Advanced Hepatocellular Carcinoma
- (2018) Ziad Bakouny et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
- (2017) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017
- (2017) Al B. Benson et al. Journal of the National Comprehensive Cancer Network
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults
- (2016) Linh Nguyen et al. ANTI-CANCER DRUGS
- Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
- (2016) Maria Pia Brizzi et al. Expert Review of Anticancer Therapy
- Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib
- (2016) Linh Nguyen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma
- (2016) Jian Liu et al. PLoS One
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- (2015) L Zhou et al. ONCOGENE
- Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
- (2014) Q. Xiang et al. CLINICAL CANCER RESEARCH
- Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
- (2014) Anna R Kwilas et al. Journal of Translational Medicine
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search